Answers are grounded in this paper and cite their sources.
Introduction: Most patients with anti-γ-aminobutyric acid-B (anti-GABA-B) receptor encephalitis present with cancer and have a poor response to immunotherapy. Moreover, septic shock, a subset of sepsis, is rarely reported in these patients during immunotherapy. Patient concerns: A 55-year-old man presented with epileptic seizure and cognitive impairment. He was previously healthy and had no family history of psychiatric disorders but had a history of smoking and emphysema. Diagnoses: Combined with the symptoms and antibody testing, anti-GABA-B encephalitis with anti-Hu antibody was diagnosed. During immunotherapy, he presented with septic shock. Further investigations and pathological examination confirmed the diagnosis of small cell lung cancer. Interventions: The patient was treated with five days of intravenous immunoglobulin (0.4/kg/d), ten days of methylprednisolone (1.0 g once a day and half the dose every three days), plus ten days of oxycarbazepine (0.3 g b.i.d.) and magnesium valproate (0.25 g b.i.d.). He received nine days of conventional treatment for septic shock in addition to meropenem (1 g intravenously every 8 hours) and etimicin (0.3 g intravenously per day). After that, he received one month of prednisone 30 mg with dose reduction 5 mg every two weeks, oxcarbazepine 0.3 g b.i.d. and valproic acid 0.25 g b.i.d. for antiepileptic treatment, olanzapine 5 mg qd + qn for antipsychotic symptoms. Outcomes: He was able to communicate with others normally and also had improved memory and clear thinking. Mini-Mental State Examination and Modified Rankin Scale were 23/30 and 1. At discharge, the titer of anti-GABA-B receptor antibody in serum (1:10) was significantly lower than the titer in serum on the day of admission (1: 100). Conclusion: Anti-GABA-B receptor encephalitis patients with cancer can respond well to immunotherapy. Personalized treatment should be considered to avoid complications like septic shock in anti-GABA-B receptor encephalitis with cancer during immunotherapy.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: